Scientific Sessions 2024  /  Featured Science: Novel Approaches to Managing Lipid Risk  /  Discussant: LIBerate-OLE, LIBerate-HeFH_OLE
Logo

American Heart Association

  206
  0

Final ID:

Discussant: LIBerate-OLE, LIBerate-HeFH_OLE

  • O'donoghue, Michelle  ( BRIGHAM WOMENS HOSP , BOSTON , Massachusetts , United States )
    • Author Disclosures:
    Michelle O'Donoghue: DO have relevant financial relationships ; Consultant:Janssen:Active (exists now) ; Consultant:NovoNordisk:Active (exists now) ; Consultant:Verve:Active (exists now) ; Consultant:AstraZeneca:Active (exists now) ; Consultant:Novartis:Active (exists now) ; Consultant:Amgen:Active (exists now) ; Researcher:AstraZeneca:Active (exists now) ; Researcher:Marea:Active (exists now) ; Researcher:Novartis:Active (exists now) ; Researcher:Amgen:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Featured Science: Novel Approaches to Managing Lipid Risk

Saturday, 11/16/2024 , 01:30PM - 02:45PM

Featured Science

More abstracts on this topic:
Efficacy and Safety of Lerodalcibep, a Third Generation PCSK9 Inhibitor, in 703 Heterozygous Familial Hypercholesterolemia Subjects in the Open Label Extension Trial

Raal Frederick, Fourie Nyda, Scott Russell, Blom Dirk, Kayikcioglu Meral, Vest Jeff, Kallend David, Stein Evan

Long-term Efficacy of Lerodalcibep in 1,468 Patients at Very High and High Risk for CVD in the 72 week Open-Label Extension Trial

Kereiakes Dean, Fourie Nyda, Scott Russell, Asprusten Emil, Yalim Zafer, Vest Jeff, Kallend David, Stein Evan

More abstracts from these authors:
Lp(a) and ASCVD: What does the causal link mean for risk reduction in practice?

O'donoghue Michelle

The New Guideline in a Global Context: Writing Committee Reply

O'donoghue Michelle, Sandner Sigrid, Tamis-holland Jacqueline

You have to be authorized to contact abstract author. Please, Login
Not Available